Long-Term Effect of Opicapone in Parkinson’s Patients Without Motor Complications: 1.5-year EPSILON Study Findings
Objective: We report motor function, motor complication and tolerability findings of the EPSILON study up to 1.5 years. Background: The 24-week, double-blind, placebo-controlled Phase III…Effectiveness of Opicapone Added to Different Levodopa Doses and LEDDs in Parkinson’s Disease: Post-Hoc Analysis of the ADOPTION Trials
Objective: To assess the efficacy of opicapone 50 mg, compared to an additional 100 mg dose of levodopa, in reducing OFF-time in Parkinson’s disease (PD)…Opicapone for OFF Motor Fluctuations in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials
Objective: To evaluate the efficacy of opicapone 50 mg in reducing OFF time and improving motor function in Parkinson’s disease (PD) patients with motor fluctuations.…Early Introduction of COMT Inhibitors at Low Levodopa Doses Improves Long-Term Motor Complications in Parkinson’s Disease: A sub-analysis of the REONPARK Study
Objective: This sub-analysis of the REONPARK study aims to identify predictive factors for the greater effectiveness of COMT inhibitors (COMTi) in alleviating motor complications in…Safety Profile of Opicapone in Elderly and Very Elderly Population
Objective: This study aimed to characterize the safety profile of opicapone (OPC) in the elderly and compare post-marketing safety between (A) very elderly patients (≥…COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Three Months Analysis Of REONPARK Study
Objective: The REONPARK study aims to evaluate COMT inhibitors (COMTi) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s disease (PD)…COMT-Inhibitors Clinical Experience In Early Motor Fluctuations. Six Months Analysis Of REONPARK Study
Objective: The REONPARK study aims to evaluate COMT inhibitors (COMTi) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s disease (PD)…Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis
Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…Safety and tolerability of overnight switching from Eetacapone to Opicapone in fluctuating Parkinson’s disease: An open-label preliminary trial in Koreans
Objective: Objectives: 1. Efficacy - Opicapone 50mg qd. to determine effectiveness of optimal dose for switching. 2. Tolerability and safety - compare symptoms and adverse…Risk of Motor Complications in Early Parkinson’s Disease Patients Treated with Opicapone in the EPSILON study: Effect of Levodopa Dose
Objective: This post-hoc analysis of the EPSILON study evaluated whether levodopa dose (<400mg/day vs. ≥400mg/day) and opicapone (OPC) timing (at double-blind [DB] or open-label extension…
- 1
- 2
- 3
- …
- 12
- Next Page »